Abstract: A method for preparing an electro-responsive silk fibroin material comprises: (1) activation of silk fibroin, (2) thiolation of silk fibroin, which involves: adding a cysteamine hydrochloride solution dropwise to the activated silk fibroin solution, adjusting the pH value of the final solution to 5-6, performing a reaction under stirring at 0° C.-4° C., taking out the resulting product, and then leaving the resulting product to stand for a reacting at 2° C.-8° C. to obtain a thiolated silk fibroin; (3) purification of the thiolated silk fibroin; and (4) preparation of an electro-responsive silk fibroin material, which involves: taking the purified thiolated silk fibroin solution, pouring same in a mold, drying same after defoaming, and demolding same to obtain the electro-responsive silk fibroin material.

Abstract: Disclosed in the present disclosure is a method for preparing an electro-responsive silk fibroin material, which method comprises the following steps: (1) activation of silk fibroin, which involves: diluting an aqueous solution of silk fibroin, then stabilizing the temperature to 0° C.-4° C., adjusting a pH value to 5-6, adding 1-10 wt % of N-hydroxysuccinimide relative to the mass of silk fibroin, then adding 2-20 wt % of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride relative to the mass of silk fibroin, mixing the resulting mixture uniformly, and performing a reaction to obtain an activated silk fibroin solution; (2) thiolation of silk fibroin, which involves: adding a cysteamine hydrochloride solution dropwise to the activated silk fibroin solution, adjusting the pH value of the final solution to 5-6, performing a reaction under stirring at 0° C.-4° C., taking out the resulting product, and then leaving the resulting product to stand for a reacting at 2° C.-8° C.

Abstract: Disclosed are a pyrazolo[1,5-a]pyridine compound, a preparation method therefor and a use thereof. Also disclosed is a pharmaceutical composition containing the compound as an active ingredient or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of a compound of formula (I) for treating and preventing diseases that can be treated with wild-type, gene fusion-type and mutant (including but not limited to G804 and G810) RET kinase inhibitors, including diseases or conditions mediated by an RET kinase.

Abstract: The present invention relates to a pyrazolo[1,5-a]pyridine derivative, a preparation method therefor, and a composition and a use thereof. Specifically, the present invention relates to the compound of formula (I) and the use thereof for the treatment and/or prevention of wild type, gene-fusion type (including but not limited to KIF5B, CCDC6 and NCOA4) and mutant type (including but not limited to V804, G810 and M918) RET kinases-related diseases, including diseases or conditions mediated by RET kinase.